EZH2 promotes malignant biological behavior in esophageal squamous cell carcinoma via EMT.
10.11817/j.issn.1672-7347.2025.240385
- Author:
Yuying JING
1
,
2
;
Kaige YANG
1
;
Yiting CHENG
1
;
Tianping HUANG
1
;
Sufang CHEN
1
;
Kai CHEN
1
;
Jianming HU
1
,
3
,
4
Author Information
1. Department of Pathology, School of Medicine, Shihezi University, Shihezi
2. 623199820@qq.com.
3. jianming.120@
4. com.
- Publication Type:Journal Article
- Keywords:
enhancer of zeste homolog 2;
epithelial-mesenchymal transition;
esophageal squamous cell carcinoma;
malignant biological behavior;
prognosis
- MeSH:
Humans;
Enhancer of Zeste Homolog 2 Protein/physiology*;
Esophageal Squamous Cell Carcinoma/pathology*;
Epithelial-Mesenchymal Transition/genetics*;
Esophageal Neoplasms/metabolism*;
Cell Proliferation;
Cell Line, Tumor;
Cell Movement;
Cadherins/genetics*;
Vimentin/genetics*;
Male;
Female;
Middle Aged;
Neoplasm Invasiveness;
Prognosis;
RNA, Small Interfering/genetics*;
Gene Expression Regulation, Neoplastic
- From:
Journal of Central South University(Medical Sciences)
2025;50(2):155-166
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Esophageal squamous cell carcinoma (ESCC) is characterized by complex pathogenesis and poor prognosis. In recent years, epithelial-mesenchymal transition (EMT) in tumor initiation and progression has attracted increasing attention. Enhancer of zeste homolog 2 (EZH2), which is aberrantly expressed in various tumors, may be closely related to the EMT process. This study aims to examine the expression and correlation of EZH2 and EMT markers in ESCC cells and tissues, evaluate the effects of EZH2 knockdown on ESCC cell proliferation, invasion, and migration, and explore how EZH2 contributes to the malignant biological behavior of ESCC.
METHODS:Bioinformatics analyses were used to assess EZH2 expression levels in ESCC. Small interfering RNA was used to knock down EZH2 in ESCC cell lines EC109 and EC9706. Cell proliferation, invasion, and migration were evaluated using cell counting kit-8 (CCK-8), wound healing, and Transwell assays. Protein and mRNA expression levels of EZH2, E-cadherin (E-cad), and vimentin (Vim) were detected by Western blotting and real time fluorogenic quantitative PCR (RT-qPCR), respectively. Immunohistochemical (IHC) staining was performed on 70 ESCC tissue samples and 40 paired adjacent normal tissues collected from the First Affiliated Hospital of Shihezi University between 2010 and 2016 to assess the expression of EZH2, E-cad, and Vim, and to analyze their associations with clinicopathological feature and patient prognosis.
RESULTS:Bioinformatics analysis showed that EZH2 was highly expressed in ESCC (P<0.001), and high EZH2 expression was associated with worse prognosis (P<0.001). CCK-8, wound healing, and Transwell assays demonstrated that EZH2 knockdown significantly suppressed the proliferation, invasion, and migration of ESCC cells (P<0.001). In addition, Vim expression was significantly reduced, while E-cad expression was significantly increased at both protein and mRNA levels in EZH2-silenced cells (all P<0.05). IHC staining analysis revealed higher expression of EZH2 and Vim and lower expression of E-cad in ESCC tissues compared to adjacent normal tissues. Kaplan-Meier survival analysis showed that low expression of EZH2 and Vim and high expression of E-cad were associated with longer survival (all P<0.05).
CONCLUSIONS:EZH2 promotes malignant biological behavior in ESCC by mediating EMT. Elevated EZH2 expression is associated with poor prognosis in ESCC patients.
